These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37141400)

  • 1. The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer.
    Fernández Montes A; Alonso Orduña V; Asensio Martínez E; Rodríguez Salas N; Torres E; Cacho Lavín D; Rodríguez Alonso RM; Falcó E; Oliva JC; Cirera L; García Gómez J; Pericay C
    Oncologist; 2023 Oct; 28(10):e902-e909. PubMed ID: 37141400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of KRAS
    Tabernero J; Taieb J; Fakih M; Prager GW; Van Cutsem E; Ciardiello F; Mayer RJ; Amellal N; Skanji D; Calleja E; Yoshino T
    ESMO Open; 2024 Mar; 9(3):102945. PubMed ID: 38471240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study.
    Liang YH; Chen KH; Shao YY
    Cancer Med; 2023 Jul; 12(14):15176-15186. PubMed ID: 37325970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients.
    Rebersek M; Mesti T; Boc M; Ocvirk J
    Radiol Oncol; 2019 Mar; 53(1):85-95. PubMed ID: 30840593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients.
    Sun DC; Shi Y; Wang YR; Lv Y; Yan H; Mao H; Wang ZK; Wu ZY; Shi WW; Dai GH
    Sci Rep; 2017 Oct; 7(1):14368. PubMed ID: 29085005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.
    Fiala O; Buchler T; Mohelnikova-Duchonova B; Melichar B; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Bartouskova M; Liska V; Topolcan O; Sedivcova M; Finek J
    Tumour Biol; 2016 May; 37(5):6823-30. PubMed ID: 26662311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
    Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
    BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.
    Chida K; Kotani D; Masuishi T; Kawakami T; Kawamoto Y; Kato K; Fushiki K; Sawada K; Kumanishi R; Shirasu H; Matsubara Y; Yuki S; Komatsu Y; Yamazaki K; Yoshino T
    Oncologist; 2021 Oct; 26(10):845-853. PubMed ID: 34232546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
    J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
    Peeters M; Douillard JY; Van Cutsem E; Siena S; Zhang K; Williams R; Wiezorek J
    J Clin Oncol; 2013 Feb; 31(6):759-65. PubMed ID: 23182985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study.
    Dadduzio V; Basso M; Rossi S; Cenci T; Capodimonti S; Strippoli A; Orlandi A; Cerchiaro E; Schinzari G; Cassano A; Martini M; Barone C
    Mol Diagn Ther; 2016 Feb; 20(1):65-74. PubMed ID: 26610798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.
    Bruera G; Cannita K; Di Giacomo D; Lamy A; Troncone G; Dal Mas A; Coletti G; Frébourg T; Sabourin JC; Tosi M; Ficorella C; Ricevuto E
    BMC Med; 2012 Nov; 10():135. PubMed ID: 23136868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
    van de Haar J; Ma X; Ooft SN; van der Helm PW; Hoes LR; Mainardi S; Pinato DJ; Sun K; Salvatore L; Tortora G; Zurlo IV; Leo S; Giampieri R; Berardi R; Gelsomino F; Merz V; Mazzuca F; Antonuzzo L; Rosati G; Stavraka C; Ross P; Rodriquenz MG; Pavarana M; Messina C; Iveson T; Zoratto F; Thomas A; Fenocchio E; Ratti M; Depetris I; Cergnul M; Morelli C; Libertini M; Parisi A; De Tursi M; Zanaletti N; Garrone O; Graham J; Longarini R; Gobba SM; Petrillo A; Tamburini E; La Verde N; Petrelli F; Ricci V; Wessels LFA; Ghidini M; Cortellini A; Voest EE; Valeri N
    Nat Med; 2023 Mar; 29(3):605-614. PubMed ID: 36864254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.
    Bencsikova B; Bortlicek Z; Halamkova J; Ostrizkova L; Kiss I; Melichar B; Pavlik T; Dusek L; Valik D; Vyzula R; Zdrazilova-Dubska L
    BMC Gastroenterol; 2015 Mar; 15():37. PubMed ID: 25888291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen.
    Bruera G; Cannita K; Giordano AV; Vicentini R; Ficorella C; Ricevuto E
    Int J Oncol; 2014 Jun; 44(6):1820-30. PubMed ID: 24715238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.
    Kubicka S; Greil R; André T; Bennouna J; Sastre J; Van Cutsem E; von Moos R; Osterlund P; Reyes-Rivera I; Müller T; Makrutzki M; Arnold D;
    Ann Oncol; 2013 Sep; 24(9):2342-9. PubMed ID: 23852309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer.
    Fakih M; Tu H; Hsu H; Aggarwal S; Chan E; Rehn M; Chia V; Kopetz S
    Oncologist; 2022 Aug; 27(8):663-674. PubMed ID: 35472176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx).
    Bruera G; Cannita K; Di Giacomo D; Lamy A; Frébourg T; Sabourin JC; Tosi M; Alesse E; Ficorella C; Ricevuto E
    BMC Med; 2013 Mar; 11():59. PubMed ID: 23497191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
    Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
    JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.